New Therapeutics in Alzheimer’s Disease
NTAD is investigating neuroplasticity – the ability of the brain to adapt and form new connections throughout life.
Scientists are looking to find out whether MEG scans which measure the electrical activity in the brain can be used to detect some of the very earliest signs of Alzheimer's disease: the loss of connections between the neurons in the brain.
NTAD will employ magnetoencephalography (MEG) to identify reliable, sensitive and tractable 'biomarkers' – biological signs – of abnormal brain structure that scientists believe is occurring early in Alzheimer’s disease. The aim is to develop a fit-for-purpose set of these identifiers based around MEG that can be used in studies which test novel interventions aimed at halting the progression of Alzheimer's disease.